Alzheimer's disease (AD) is an age-related disease characterized by loss of memory and disrupted thinking that is associated with altered energy metabolism. Variants of an important enzyme of energy metabolism, dihydrolipoamide dehydrogenase (dld), have been genetically linked to late-onset AD. Moreover, reduced activity of DLD-containing enzyme complexes is associated with AD progression. To understand how energy metabolism influences AD progression, we exposed C. elegans expressing human Aβ peptide to the chemical inhibitor of DLD, 2-methoxyindole-5-carboxylic acid (MICA). Expression of human Aβ in C. elegans causes a variety of pathologies that can be used to monitor the efficacy of treatments against proteotixicity. We found that MICA alleviated the Aβ-induced paralysis and improved cholinergic neurotransmission in C. elegans that express Aβ in muscle cells. MICA also reduced both hypersensitivity to serotonin and perturbation of chemotaxis associated with neuronal expression of human Aβ. Furthermore, low doses of MICA helped to alleviate an Aβ-mediated decrease in fecundity. Protection against AD pathogenesis by MICA in the C. elegans model was associated with a decrease in Aβ oligomerization that could be reversed by the calcium ionophore, A23187. MICA also caused a decrease in oxidative stress, which could also contribute to the protective effect of MICA against Aβ toxicity.
Introduction
Despite 100 years of research into Alzheimer's disease (AD), the mechanism of disease initiation and progression is poorly understood. Overproduction and deposition of extracellular amyloid beta (Aβ) plaques is a key indicator of disease progression that is associated with cognitive impairment, neuronal loss and dementia (Castellani and Perry, 2014; Hyman et al., 2012) . In addition to the presence of Aβ plaques, reduced glucose energy metabolism and diminished activities of mitochondrial enzymes were found in brain tissue from late-stage AD patients (Mosconi, 2013; Shoffner, 1997; Vlassenko et al., 2012; Vlassenko et al., 2010) . This decrease in energy metabolism could be (i) caused by disease progression as several late-stage postmortem studies found reduced energy metabolism in AD brain samples (Hooijmans et al., 2007; Hoyer, 1991; Hoyer, 2000; Hoyer, 2004; Hunt et al., 2007) , or (ii) a cellular response designed to limit damage due to Aβ-toxicity. Recent studies on post mortem brains at various stages of disease progression support the second interpretations as the down regulation of energy metabolism occurs too early in disease progression to be either a cause or consequence of tissue damage. Rather, the authors suggested that reduced energy metabolism is a protective measure designed to minimize neuronal activity, thereby decreasing the repair burden (Liang et al., 2012; Sun et al., 2012) . Regardless of the interpretation, the evidence suggests an intimate link between AD and energy metabolism.
The limited availability of AD affected brains from various stages of disease progression makes it difficult to investigate the role of energy metabolism in the process. However, a decrease in the activity of three dihydrolipoamide dehydrogenase-containing mitochondrial enzymes of energy metabolism, pyruvate dehydrogenase (PDH), α-ketoglutarate dehydrogenase (KGDH) and branched chain α-keto acid dehydrogenase (BCKDH has been observed in AD (Gibson et al., 2012; Shi et al., 2011; Simoncini et al., 2015) . PDH links glycolysis to the TCA cycle and is a major control point in the regulation of aerobic respiration. Dichloroacetate, an activator of PDH induces oxidative phosphorylation and increases neuronal sensitivity to Aβ (Newington et al., 2011) . In contrast, the glucose analogue, 2-deoxy-D-glucose, inhibits both glycolysis and aerobic respiration, and reduces Aβ toxicity in mouse models as well (Vilalta and Brown, 2014; Yao et al., 2011) . KDGHC is the ratelimiting step of the TCA cycle (Shoffner, 1997) , and may have a similar role in suppressing the rate of aerobic respiration to reduce AD pathogenesis.
There is a variety of genetic evidence that links dihydrolipoamide dehydrogenase (DLD) to AD, including genetic variants associated with the disease in an Ashkenazi Jewish population (Brown et al., 2007) . This supports the evidence from changes in the activity of DLD-containing enzyme complexes mentioned above. In the current study we use a chemical inhibitor of DLD enzyme activity known as 5-methoxyindole-2-carboxylic acid (MICA) to determine whether it also can alleviate Aβ toxicity in C. elegans that express human Aβ.
MICA is a hypoglycemic agent that has been suggested as a possible drug to treat type 2 diabetes (T2DM) (Bauman and Hill, 1968; Bauman and Pease, 1969; Gold, 1974; Schillinger and Loge, 1976; Ueki et al., 1985) . Evidence indicates that the metabolic disease diabetes increases the risk of AD (Nguyen et al., 2014; Sebastiao et al., 2014; Verdile et al., 2015) . As both AD and diabetes share many pathological features (Ahmad, 2013; Rosales-Corral et al., 2015) , it is possible that drugs used to lower hyperglycemia such as MICA might be effective in AD treatment. Although the exact mechanism whereby MICA alleviates hyperglycemia is not fully understood, MICA modifies cellular glucose levels by inhibiting glucose metabolism rather than insulin sensitivity (Arneric et al., 1984; Bauman and Pease, 1969; Hanson et al., 1969) . Consistent with its action as an inhibitor of DLD, MICA inhibits the oxidation of the keto acid substrates of the enzyme complexes that contain DLD. This was reflected in reduced DLD enzyme activity in mitochondria of mice/rats treated with MICA (Bauman and Hill, 1968; Haramaki et al., 1997) . Inhibition of DLD by MICA was reversible by increasing intracellular calcium levels using the calcium ionophore A23187 (CaI) (Mitra and Shivaji, 2004; Nichols and Denton, 1995) .
There is no evidence regarding the role of MICA on neurodegeneration, though one possible mechanism by which MICA could influence neurodegeneration is by modifying energy metabolism. Our results showed that MICA protects against Aβ-mediated toxicity in C. elegans that express human Aβ. The protective effect of MICA is associated with a decrease in Aβ oligomerisation. In our study, the protective effects of MICA can be reversed using MICA inhibitor calcium ionophore A23187 (CaI).
Materials and methods

Nematode strains
C. elegans strains used in this study are: wild type strain N2 (Bristol) long-lived, stress resistant dld-1 mutant, dld-1(wr4) (Cheng et al., 2003; Schlipalius et al., 2012) , and the transgenic strains that express the human β-amyloid peptide in muscle cells. CL2006 (dvIs2 [pCL12(unc-54/hu-Aβ42) + pRF4]), which produces the human Aβ 42 peptide constitutively and CL4176 (smg-1 ts [myo-3/Aβ42 long 3 / -UTR]), in which Aβ 42 peptide expression is increased when the temperature is increased from 16°C to 23°C. The use of these strains as a worm model of AD was documented previously (Link, 1995) . We also used strain CL2355 (dvIs50 [pCL45 (snb-1::Abeta 1-42::3′ UTR(long) + mtl-2::gfp] I), in which Aβ is also expressed under temperature control, though in this case the peptide is expressed pan-neuronally. The control strain for CL2355 was CL2122 (dvIs15(mtl-2::gfp) (Link, 1995; McColl et al., 2009; McColl et al., 2012; Wu et al., 2006) . All the strains were obtained from the Caenorhabditis Genetics Center (CGC).
Culture conditions
Worms were maintained on nematode growth medium (NGM) seeded with E. coli OP50 at 20°C, except strains CL4176 and CL2355, which were maintained at 16°C to suppress Aβ expression. Synchronized cultures for bioassays were obtained using the standard bleaching procedure (Stiernagle, 2006) . Briefly, gravid hermaphrodites were exposed to a freshly prepared alkaline bleach solution (0.75 N NaOH + 1.5 N NaOCl). The worms were incubated in the bleach solution for 5 min at room temperature followed by centrifugation at 1100 RPM for 1 min at room temperature. The supernatant was then discarded, and the pelleted eggs were resuspended in M9 buffer (6 g/L Na 2 HPO 4 ; 3 g/L KH 2 PO 4 ; 5 g/L NaCl; 0.25 g/L MgSO 4 •7H 2 O. Washing with M9 buffer was repeated 3 more times, after which the eggs were suspended in M9 buffer and allowed to hatch overnight on an orbital shaker. The resulting L1 larvae were shifted to the fresh NGM agar plates seeded with E. coli to initiate growth. Aβ inducible transgenic worms were initially cultivated at 16°C for 36 h after which the temperature was increased to 23°C for 36 h except for the paralysis assay for which the temperature was further increased to 25°C to maximize the effect of the Aβ transgene. Aβ constitutive expressing worms were cultured at 20°C Phenotypes of the worms were monitored by visual observation under a microscope or quantified using the WormScan procedure (Mathew et al., 2012) .
Gene suppression by RNAi
The E. coli strain SJJ_LLC1.3 (Source Bioscience), which expresses double-stranded RNA of the dld-1 gene, was fed to the worms to trigger dld-1 gene suppression (Kamath and Ahringer, 2003) . Briefly, the bacteria were cultured in LB medium containing 100 μg/mL ampicillin overnight with shaking at 37°C. 300 μL of this bacterial culture was transferred to NGM plates containing 100 μg/mL ampicillin and 1 mM IPTG. The plates were incubated at 25°C overnight to allow the bacteria to grow. Synchronized L1 worms were transferred to the bacterial plates and kept at 16°C for 36 h. After a further 36 h at 20 or 25°C, the worms were ready for use in gene expression, protein abundance and worm activity assays as described below. Mock gene suppression controls were treated in exactly the same way except that the worms were fed bacterial strain (HT115), which contained the plasmid vector without any specific gene fragment corresponding to a C. elegans gene.
Paralysis assay
Synchronized L1 stage CL4176 worms were transferred to NGM plates. To assess the role of chemical inhibition on paralysis behaviour of Aβ transgenic strains, different concentrations of chemicals were used in normal NGM plates. Transgenic worms were exposed to these chemicals continuously -before, during and after the induction of Aβ expression. After 36 h at 16°C, worms were shifted to 25°C and scored for paralysis every 24 h. Scoring began 24 h after the temperature was raised to increase transgene expression.
Aldicarb and levamisole assays
Synchronized L1 worms were placed at 20°C on NGM plates or NGM plates supplemented with 5 mM MICA that had been seeded with a lawn of OP50 E. coli. The worms were allowed to grow until they reached the L4 stage of development, at which time they were shifted to new NGM plates containing 1 mM aldicarb, an ACh sterase inhibitor (Mahoney et al., 2006) or 0.2 mM levamisole, a cholinergic agonist (Lewis et al., 1987) . Worms that had matured in the absence of MICA were exposed to the toxin without MICA and those exposed to MICA during maturation were, likewise, exposed to MICA during exposure to the toxin. The number of active worms was counted every half an hour until all worms became paralysed.
Serotonin assay
To determine the level of Aβ-induced serotonin hypersensitivity, serotonin (creatinine sulfate salt) was first dissolved in M9 buffer to 1 mM as described previously (Dosanjh et al., 2010; Zhang et al., 2005) . Synchronized worms were then washed with M9 buffer, and worms were transferred to 200 μL of the 1 mM serotonin solution in 12-well assay plates. The worms were scored as either active or paralysed after 5 min.
Chemotaxis assay
The chemotaxis assay was performed as described previously (Bargmann et al., 1993; Wu et al., 2006) . Worms were placed on the center of the assay plate, which was then incubated for 1 h at 20°C. Attractant containing 1 μL of odorant (0.1% benzaldehyde in 100% ethanol) was added in a spot on one edge of the plate with 1 μL of 100% ethanol as a control on the opposite side of the plate. 1 μL of 1 M sodium azide was added to each of the two spots to immobilize the animals once they had migrated to one or the other destination. The chemotaxis index (CI) was calculated as ([number of worms at the attractant location -number of worms at the control location]/total number of worms on the plate).
Egg viability assay
Transgenic Aβ strain CL2355 and its no-Aβ control strain CL2122 were synchronized as described under culture conditions above. After synchronization worms were grown at 16°C on NGM agar plates seeded with OP50 bacteria that either contained or did not contain 5 and/or 10 mM MICA. Once the worms reached maturity at three days of age, 10 individuals in each of three replicates were transferred to fresh agar plates of the same composition and shifted to 23°C. Egg viability was determined as the percentage of eggs that were able to hatch over the next 3 days.
Chemical inhibition of DLD-1 with MICA in C. elegans
Briefly, fresh NGM plates containing 1, 2.5, 5, 10, 25 and 50 mM concentrations of 5-methoxyindole-2-carboxylic acid (MICA) were prepared. As MICA is partially soluble in water, complete solubilization was achieved by adding a drop wise 5 N sodium hydroxide until MICA becomes clearly soluble in water. Paralysis assay was scored for worms treated with and without MICA after 36 h temperature up-shift at 25°C.
Reversal of MICA-mediated effects with a calcium ionophore
Transgenic worms were synchronized and placed at NGM plates containing dld-1 RNAi and/or 5 mM MICA for 36 h at 16°C and afterwards up-shifted to 23°C for an additional 36 h. L4 stage worms were next transferred to NGM plates containing different concentrations of calcium ionophore A23187 (CaI) ranging from 15 to 45 μM with and without presence of 5 mM MICA and/or dld-1 RNAi at 25°C. Worms were counted for paralysis until all worms became paralysed. To check whether absence or induction of calcium in NGM medium interferes with MICA-mediated protection, transgenic worms were placed on NGM plates containing 0. 1, 2.5, 5, 7.5, and 10 mM CaCl 2 and assessed for paralysis.
Oxidative stress measurement
Reactive oxygen and reactive nitrogen species (ROS/RNS) levels were measured using 2′,7′-dichlorofluorescein diacetate (DCF-DA) as described previously (Lee et al., 2010) . Briefly, worms were synchronized and placed on NGM plates containing either 0 mM or 5 mM MICA that had been seeded with E. coli OP50 (Dosanjh et al., 2010) . Worms were incubated for 36 h at 16°C followed by a temperature upshift for a further 36 h at 23°C, after which they were washed with PBS three times and snap frozen in 250 μl cell lysis solution. To prepare extracts, worms were sonicated followed by centrifugation at 14000 rpm for 30 min. The supernatant was collected and protein in the extract was quantified using the Pierce Coomassie (Bradford) protein assay kit (Thermo Scientific) measured on a Nanodrop spectrophotometer. Supernatant containing 25 μg of protein was pre-incubated with 250 μM DCF-DA in 100 μl of 1× PBS at 37°C for 1 h. Fluorescence intensity (excitation wavelength 485 nm and emission wavelength 535 nm) was measured using a SpectraMax M3 fluoremeter (Molecular Devices, Sunnyvale, USA). The background fluorescence of 250 μM DCF-DA was subtracted from each sample.
Hydrogen peroxide (H 2 O 2 ) levels were measured spectrophotometrically using toluidine blue as described previously by Sunil et al. (Sunil and Narayana, 2008) . Worm extracts were prepared and protein concentrations quantified as for the DCF-DA assay protocol. For each 25 μg of protein we added 20 μl 2% potassium iodide, 20 μl 2 M HCl, 10 μl 0.01% toluidine blue and 40 μl 2 M sodium acetate. The contents were mixed and absorbance was measured at 628 nm against a standard curve based on known concentrations of H 2 O 2 .
Western blotting of Aβ
Aβ was identified in C. elegans strains by immunoblotting after separation of proteins on a 16% Tris-Tricine gel. A standard western blotting protocol was used except that SDS was omitted from the transfer buffer (Mahmood and Yang, 2012) . Briefly, synchronized L2 worms were incubated at 23°C for 36 h and then washed with distilled water, and quickly frozen in liquid nitrogen. Flash frozen worms were either stored at −80°C or sonicated twice in the ice-cold cell lysis buffer (50 mM HEPES, pH 7.5, 6 mM MgCl 2 , 1 mM EDTA, 75 mM sucrose, 25 mM benzamide, 1 mM DTT and 1% Triton X-100 with proteinase and phosphatase inhibitors 1:100 ratio). After sonication, the lysate was centrifuged at 10000 rpm to remove insoluble debris and total protein in the supernatant was determined using the Pierce Coomassie (Bradford) protein assay kit (Thermo Scientific) measured on a Nanodrop spectrophotometer. From each sample,~100 μg of total protein was precipitated with acetone and dissolved in Novex® Tricine SDS sample buffer (LC1676, Invitrogen) by heating to 99°C for 5 min. Samples were subjected to gel electrophoresis at 100 V for 2.5 h using separate cathode (100 mM Tris, 100 mM Tricine, 0.1% SDS, pH 8.3) and anode (0.2 M Tris, pH 8.8) running buffers. Proteins were wet transferred onto nitrocellulose membranes by electroblotting in the transfer buffer (35 mM glycine, 48 mM Tris (pH = 8.8) and 20% methanol) for 70 min at 100 V and stained with Ponceau S (0.1% Ponceau S in 1% acetic acid) for 5 min following de-staining with 10% acetic acid (5 min) and washing under water (5 min). The membranes were blocked overnight in 5% skim milk at 4°C to prevent non-specific binding of antibodies.
To detect Aβ, the primary antibody binding was done using the mouse Aβ monoclonal antibody 6E10 (Covance) at 1:1000 dilution in TBS (50 mM Tris, 150 mM NaCl, pH 7.6) containing 1% skim milk for 3-4 h at room temperature followed by three washes with TBS-T of five minutes each. For DLD-1 detection, anti-lipoamide dehydrogenase antibody (ab133551) was used. The same procedure was repeated for DLD-1 detection except 5%BSA in 1× TBST was used for anti-body detection.
Anti-mouse IgG alkaline phosphatase antibody produced in goat (A3562, Sigma), and anti-rabbit IgG alkaline phosphatase antibody produced in goat (A3687, Sigma were used as secondary antibody at 1:10000 dilutions in TBS containing 1% skim milk or in 1% BSA in 1× TBST. Secondary antibody staining was done for 1 h at room temperature. After washing the membrane with TBST, the proteins were detected using the BCIP/ NBT substrate system (Sigma) or the BCIP/ NBT kit (002209) from Life Technologies dissolved in 1 M Tris (pH 9.0).
Quantitative RT-PCR and immunoblotting confirmation
Aβ mRNA levels in transgenic worms either exposed or not exposed to 5 mM MICA were quantified using Rotor-Gene Q (QIAGEN) thermocycler. Briefly, total RNA was extracted using the acid-phenol (Trizol) method and converted to single-stranded cDNA using Invitrogen SuperScript cDNA synthesis kit following the prescribed protocol. Gene-specific primers were as follow: Aβ forward primer CCGACATGACTCAGGATATGAAGT, Aβ reverse primer CACCATGAGT CCAATGATTGCA; dld-1 forward primer GATGCCGATCTCGTCGTTAT, dld-1 reverse primer TGTGCAGTCGATTCCTCTTG; act-1 forward primer CGCTCTTGCCCCATCGTAAG, act-1 reverse primer CTGTTGGAAGGTG GAGAGGG; gapdh-2 forward primer TTCTCGTGGTTGACTCCGAC, and gapdh-2 reverse primer AGGGAGGAGCCAAGAAGGTAAC. The PCR conditions were 95°C for 30 s followed 35 cycles of 95°C for 20 s, 55°C for 30 s, and 72°C for 40 s. Following amplification, a melting curve was determined during a temperature ramp from 72°C to 95°C. For qPCR quantification, SYBR® Green JumpStart™ ReadyMix™ (Sigma) was used.
Statistical analysis
GraphPad prism 7.03 was used for graph production and statistical analysis. Paralysis curves were compared using the log-rank (MantelCox) test. Pairwise treatments were analyzed for statistical significance by independent student's t-test. Anova was used to compare statistical difference among 3 or more groups. A p value of < 0.05 was considered statistically significant.
Results
The influence of energy metabolism on Alzheimer's disease is still unclear though a significant correlation exists between a decline in glucose metabolism and the progression of late-onset AD (Ahmad, 2013; Akhtar et al., 2016; Furst and Lal, 2011; Hoyer, 1991; Hoyer, 2000; Nilsen et al., 2011; Vilalta and Brown, 2014; Yao et al., 2011) . Two mutually exclusive hypotheses have been proposed, that declining energy metabolism exacerbates disease progression or that it is a protective response to AD that slows progression of the disease. In work that we will publish elsewhere, we found that suppression of energy metabolism by RNAi of the dld-1 gene results in significant protection against Aβ proteotoxicity in C. elegans models of AD. Based on this finding, we reasoned that the DLD-1 enzyme inhibitor 2-methoxyindole-5-carboxylic acid (MICA) might act as a small molecule therapeutic agent in the treatment of AD. Here we show that MICA reduces Aβ-mediated, age-dependent paralysis, impaired ACh neurotransmission, and impaired behaviour in the AD models.
3.1. MICA up to 10 mM does not alter dld-1 gene or protein expression MICA is a known inhibitor of the DLD enzyme (Bauman and Hill, 1968; Hanson et al., 1969) , but its effect on dld-1 transcript and protein levels is not known. We find that dld-1 RNAi was able to suppress the dld-1 transcript levels in the CL4176 strain by approximately 75% (p = 0.015) (Fig. 1A) and suppressed DLD-1 protein abundance by approximately 70% (Fig. 1B , p = 0.006). Exposure to 5 mM MICA caused no significant change in transcript abundance (p = 0.172). Likewise, concentrations of MICA from 1 to 10 mM have no significant effect on DLD-1 protein expression (p > 0.05). However, 15 mM MICA causes a significant increase in protein abundance (p = 0.004) (Fig. 1C) .
MICA alleviates Aβ-induced pathology in transgenic C. elegans
While MICA did not affect either dld-1 gene expression or protein abundance, it is known to inhibit DLD protein activity and to reduce downstream energy metabolism (Bauman and Hill, 1968; Hanson et al., 1969) . The suppression of dld-1 by RNAi in C. elegans is associated with stress resistance (Butler et al., 2013; Schlipalius et al., 2012) . This suggests that MICA will be a useful tool with which to investigate the relationship between metabolic rate and AD, using Aβ-toxicity as an indicator.
Aβ-mediated toxicity in worms is associated with age-dependent paralysis (Link, 1995) . To determine whether MICA can delay Aβ-mediated paralysis, worms of strain CL4176 that contain a temperature inducible Aβ transgene were exposed to MICA continuously, before, during and after induction of Aβ expression. The time to 100% paralysis of the 0 mM MICA control was 48 h. Both 5 mM and 10 mM MICA significantly delayed the time to paralysis, though the 5 mM treatment had the greatest effect (120 h, p < 0.0001). Interestingly, outside the therapeutic range, at low (2.5 mM) and at high (25 mM) concentrations, MICA had no effect on paralysis (p > 0.05). At an extremely high dose (50 mM), MICA worms ceased moving within 24 h (p = 0.01) (Fig. 2A) . Suppression of the dld-1 gene by RNAi had a protective effect even greater than that of 5 mM MICA (Fig. 2A) .
As DLD-1 inhibition by MICA and suppression of the dld-1 gene by RNAi can both alleviate Aβ-mediated paralysis, we tested the two treatments in combination to determine whether the effect of MICA was mediated through DLD-1. To accomplish this, we compared the effect after 24 h of 5 mM MICA and RNAi of the dld-1 gene individually as well as in combination. Suppression of the dld-1 gene by RNAi doubled the number of active worms at 24 h. MICA also increased the percentage of active worms to a level that, while lower, was statistically indistinguishable from the percentage of worms that remained active in response to dld-1 gene suppression (67.5 ± 3.7 vs 85.5 ± 3.5, p = 0.071) (Fig. 2B) . The effect of the combined treatment was essentially identical to that of dld-1 RNAi but was significantly more protective than MICA alone (67.5 ± 3.7 vs 88.5 ± 4.9 (p = 0.035). Thus, the protective effect of MICA is likely mediated through its effect on the DLD-1 enzyme.
Aβ expression in worms impairs cholinergic neurotransmission and associated functions like muscle contraction and movement (Brown and Luo, 2009) . Because the presence of Aβ blocks the release of acetylcholine (Ach), worms that express Aβ are protected against the acute paralysis that is caused by hyperexcitation of the cholinergic system. Thus, acute paralysis caused by two cholinergic agonists, aldicarb, an ACh esterase inhibitor (pre-synaptic effect) and levamisole, a receptor agonist (post-synaptic effect) is delayed in strains that express Aβ (Diomede et al., 2014; Oh and Kim, 2017; Saharia et al., 2012; Xin et al., 2013) . To check whether MICA restores normal ACh neurotransmission (i.e. susceptibility to acute paralysis by cholinergic agonists), the CL2006 strain that constitutively expresses Aβ in muscle cells was exposed to aldicarb or levamisole. In our study, MICA restored sensitivity to aldicarb, reducing the time to paralysis by 33% compared to worms that were not exposed to MICA (from 180 to 120 min) (p < 0.0001) (Fig. 3A) . In contrast, paralysis due to the postsynaptic receptor agonist, levamisole, was only decreased by 12.5% (from 240 min to 210 min) (p = 0.0001) after MICA treatment (Fig. 3B) . As MICA did not change the paralysis profile of either wild type or dld-1 mutated worms (Fig. S1 ), the increase in ACh neurotransmission is most likely the result of a decrease in cholinergic inhibition by Aβ.
We next determined whether MICA was also able to reverse the negative effects of Aβ expression in the nervous system using strain CL2355 and its matched control CL2122. In AD, Aβ is primarily expressed in neurons. Assays for cellular dysfunction due to neuronal expression of Aβ in C. elegans include impaired chemotaxis, serotonin hypersensitivity, egg laying and egg hatching (Machino et al., 2014; Wu et al., 2006) .
Neuronal expression of Aβ in strain CL2355 significantly reduced chemotaxis toward the attractant benzaldehyde compared to non-Aβ control worms (Chemotaxis index, 0.062 ± 0.014 vs 0.219 ± 0.06, p = 0.004). MICA exposure significantly improved chemotaxis of strain CL2355 (0.062 ± 0.014 vs 0.138 ± 0.026, p = 0.018), which was not statistically distinguishable from that of the MICA treated control strain (0.138 ± 0.026 vs 0.185 ± 0.035, p = 0.12) (Fig. 4A) . However, MICA treatment did not affect chemotaxis in the non-Aβ control worms CL2122 (0.185 ± 0.035 vs 0.219 ± 0.06, p = 0.70).
C. elegans exposed to exogenous serotonin become paralysed. Neuronal expression of Aβ (CL2355) increases sensitivity to serotonin, exacerbating paralysis relative to the matched control (CL2122) (70.6 ± 4.5% vs 36.3 ± 5.5%, p = 0.007) (Wu et al., 2006) . MICA did not change the paralysis level of the CL2122 worms (36.3 ± 5.5% vs 40.3 ± 6.3%, p = 0.859) but was able to reduce paralysis in strain CL2355 in which Aβ was expressed (70.6 ± 4.5% vs 52.6 ± 8.1, p = 0.01). The fraction of CL2355, MICA-treated worms that were paralysed, however, did not return to the CL2122 MICA-treated control level (52.6 ± 8.1 vs 40.3 ± 6.3%, p = 0.044) (Figs. 4B) .
The presence of Aβ is also known to decrease fecundity and delay egg hatching in C. elegans (Machino et al., 2014) , so we tested whether MICA could reverse these effects. The fecundity of the Aβ strain CL2355 was indeed lower than its matched control (157 ± 8 vs 270 ± 8, p < 0.0001) (Fig. 4C) . 5 mM MICA significantly improved fecundity in CL2355 worms (157 ± 8 vs 198 ± 8, p = 0.004), but this increase failed to restore fecundity to the level of the untreated control (198 ± 8 vs 270 ± 7, p = 0.0001). 5 mM MICA also reduced fecundity of CL2122 control worms (270 ± 7 vs 222 ± 15, p = 0.01) and 10 mM MICA caused a decrease in fecundity for both strains (Fig.  S2) . It is likely that at higher doses, MICA inhibits energy metabolism due to inhibition of DLD-1, which triggers the reduction in egg laying independently of Aβ.
Aβ expression also impedes egg hatching in worms with only 13.7% of control (CL2122) eggs remaining unhatched after 24 h compared to 61.8% of eggs from the Aβ transgenic strain (CL2355) (p < 0.0001) (Fig. 4D) . Hatching was greatly improved in the CL2355 strain after exposure to 5 mM MICA, with only 27.5% of CL2355 eggs remaining unhatched after 24 h (p = 0.001). By day two, 8% of control eggs and 37.6% of eggs from the Aβ transgenic strain remained unhatched (p = 0.0009). In contrast, Aβ transgenic worms treated with 5 mM MICA showed a significant improvement with only 17.8% (p = 0.007) of eggs remaining unhatched. In the Aβ transgenic strain, egg hatching was impeded such that 17.5% were still unhatched even by day three.
Protective effects of DLD-1 inhibition can be reversed by calcium ionophore (CaI)
Although we found that MICA can protect against Aβ, it is toxic and has a narrow effective dose range (Hanson et al., 1969 ; Schillinger and Fig. 1 . MICA does not affect dld-1 transcript levels. Transcript and protein quantification was carried out on synchronized L4 stage C. elegans of strain CL4176 that expresses Aβ in muscle. The nematodes were either subjected to RNAi of the dld-1 gene or treated with MICA at the indicated concentrations. The nematodes were initially cultured for 36 h at 16°C, followed by 36 h at 25°C to induce transgene expression before RNA or protein extraction. A) Quantification of relative dld-1 mRNA levels by RT-PCR, in CL4176, CL4176 in which the dld-1 gene has been suppressed by RNAi or CL4176 treated with 5 mM MICA. B) Immunoblot assay of total soluble protein from cell lysate of CL4176 or CL4176 in which the dld-1 gene has been suppressed by RNAi. DLD-1 protein levels were detected using the anti-DLD antibody and were normalized to tubulin levels using an anti-tubulin antibody. C) Immunoblot assay of total protein extracted from CL4176 treated with different concentrations of MICA. Graphs show results from three independent replicates. Bars = Mean ± SD. Loge, 1976) . If MICA is to be used effectively against AD, it is imperative that we understand the basis of its toxicity. In this regard, MICA is known to influence calcium signaling, as inhibition of DLD by MICA causes a decrease in intracellular calcium that can be reversed by the calcium ionophore A23187 (CaI) (Panneerdoss et al., 2012) . This finding raises the possibility that CaI might also reverse the effects of dld-1 inhibition on strains that express Aβ. To test this hypothesis, we assessed the effect of CaI on Aβ-mediated paralysis alone or in the presence of either 5 mM MICA or dld-1 gene suppression by RNAi.
Doses of CaI up to 30 μM have no effect on Aβ-mediated paralysis, whereas higher doses increased paralysis (Fig. 5A) , a result that is consistent with the antagonistic effect of CaI on MICA. For Aβ-expressing worms treated with a maximally protective dose of 5 mM MICA, a CaI dose of 30 μM partially reversed the protective effect. At 35 μM CaI, paralysis was equivalent to that observed in Aβ expressing control worms without MICA treatment (Fig. 5B) . 35 μM CaI also completely reversed the protection against Aβ expression provided by suppression of the dld-1 gene through RNAi (Fig. 5C ). Increasing the calcium in the growth medium from 1 mM to 10 mM had no effect on the Aβ-mediated paralysis phenotype (Fig. 5D) .
MICA and CaI modulate Aβ protein oligomerization without affecting Aβ peptide levels
In our study, MICA successfully reduced the Aβ toxicity in worms that express Aβ in either muscle cells or neurons of C. elegans. MICA is known to inhibit DLD-1 enzyme activity and CaI reverses this suppression, but we wished to confirm that there were no confounding effects on Aβ gene expression that would lead us to misinterpret how MICA and CaI might influence the C. elegans model of Aβ. Quantitative PCR revealed no change in mRNA levels of the Aβ transgene after RNAimediated suppression of the dld-1 gene, treatment with MICA, or exposure to CaI (Fig. 6A) .
We also monitored the effect of dld-1 RNAi, MICA and CaI on ex vivo oligomerization of Aβ, because an increase in oligomerization induced by CaI is one way that it could overcome the protective effect of the other treatments (Giuffrida et al., 2009) . We used the Aβ specific antibody (6E10) on western blots to detect Aβ monomers and oligomers (Fig. 6B) . Fig. 6B also represents quantification of respective band intensities normalized to the amount of β-actin in each protein sample from three independent experiments.
Our results showed that MICA significantly increases the abundance of Aβ monomers when compared to control (~4 kDa: 0.24 ± 0.09 vs Fig. 2 . MICA reduces paralysis due to Aβ expression in muscles of C. elegans. A) L1 nematodes of strain CL4176 Temperature inducible Aβ expressing worms were cultured on medium containing MICA at concentrations ranging from 2.5 to 50 mM. Protection against paralysis was assessed relative to protection due to RNAi of the dld-1 gene [(+) dld-1] or the untreated strain [CL4176]. T = 0 refers to the time of induction of Aβ expression by temperature up-shift to 25°C. B) The effect of co-treatment with 5 mM MICA and dld-1 suppression by RNAi after 24 h of temperature induction. Bars = mean ± SD. Graphs show the average percentage values of active worms between treatments from three independent trials of 60-80 worms. Statistical analysis employed the log-rank survival test. Whereas dld-1 RNAi and MICA each cause an increase in monomer, simultaneous exposure to 35 μM CaI caused a decrease in oligomers, reversing the protection resulting from the original interventions. Thus, the levels of 4 kDa monomers is decreased and 9 kDa Aβ oligomers increase to the level of the CL4176 control strain without intervention (Fig.6B) . It was interesting that on its own, 35 μM CaI does not increase Aβ oligomerization, but rather decreases Aβ~16 kDa oligomers (0.30 ± 0.04 vs 0.02 ± 0.07, p = 0.002) and~20 kDa (0.33 ± 0.04 vs 0.07 ± 0.04, p = 0.012) when compared to control. No effect was observed on 9 kDa oligomers. At the same time, the abundance of 4 kDa monomer increased from 0.24 ± 0.09 to 0.65 ± 16, p = 0.02. Fig. 4 . MICA alleviates impaired chemotaxis, hypersensitivity to serotonin and reduced fecundity caused by neuronal expression of Aβ. L1 stage nematodes of strains CL2355 (neuronal Aβ) and their matched control CL2122 were cultured with or without 5 mM MICA for 36 h at 16°C plus 25°C for an additional 36 h to induce transgene expression. A) Impairment of chemotaxis due to Aβ expression is significantly alleviated by exposure to 5 mM MICA. B) Hypersensitivity toward serotonin resulting from neuronal expression of Aβ is substantially reduced by exposure to 5 mM MICA. C) Egg production that is reduced due to Aβ expression is partially restored by MICA. D) Egg hatching is delayed by neuronal expression of Aβ, but this effect is alleviated by MICA treatment. 30-50 worms were used for each treatment in each of three independent trials, except for fecundity and egg hatching assays where 10 worms were used in each of three independent trials. Bars = Mean ± SD.
MICA reduces oxidative stress in Aβ expressing worms
Another possible mechanism through which MICA could decrease the toxicity of Aβ is via a decrease in reactive oxygen or reactive nitrogen species (ROS/RNS) as these reactive molecules can induce aggregation of Aβ (Goldsbury et al., 2008; Misonou et al., 2000; Pajak et al., 2016) . DLD itself can generate significant amounts of ROS (superoxide), so suppression of DLD activity could lead to a decrease in superoxide production (Murphy, 2009; Tahara et al., 2007) . To explore this possibility, we measured the cellular ROS/RNS levels using DCF-DA. Our results showed that MICA lowered the ROS/RNS levels of the Aβ-expressing, strain CL4176 (5266.5 ± 883vs1610.6 ± 838.5, p < 0.001) (Fig. 7) .
The superoxide that is produced by DLD is readily converted into hydrogen peroxide (H 2 O 2 ). Quantification of H 2 O 2 is therefore a good indicator of DLD-generated oxidative stress. We measured the H 2 O 2 levels in the worm's extracts spectrophotometrically using toluidine blue. Addition of MICA significantly lowered the H 2 O 2 levels in Aβ expressing worms when compared to non-treated (24.1 ± 1.4 vs 12.2 ± 0.6, p < 0.001). This MICA-mediated decrease in ROS may also protect against Aβ-toxicity.
Discussion
MICA is a potent inhibitor of dihydrolipoamide dehydrogenase, a key enzyme of energy metabolism that is implicated in Alzheimer's disease. Specifically, the activities of two enzyme complexes that contain DLD as a subunit, are diminished in AD (Gibson et al., 2012; Gibson et al., 1988; Gibson et al., 1998; Mastrogiacoma et al., 1996) . This may implicate these complexes in the pathology of AD or may suggest that their suppression is a protective response to AD pathology. Mutation in the dld-1 gene in C. elegans or suppression of the gene by RNAi results in stress resistance and an extended lifespan (Butler et al., 2013; Cheng et al., 2003; Schlipalius et al., 2012) , which supports the latter hypothesis. We have used MICA to determine whether inhibition of the DLD enzyme influences Aβ pathology, a hallmark of AD, and a progressive, age-related human disease.
In our study, RNAi-mediated suppression of the dld-1 gene resulted Fig. 5 . The calcium ionophore A23187 (CaI) can reverse the alleviation of Aβ-mediated paralysis by MICA. Aβ expression was induced in muscles of strain CL4176 by a temperature up shift. Various concentrations of CaI were then tested for their ability to interfere with the therapeutic effect of either 5 mM MICA or inhibition of the dld-1 gene by RNAi on Aβ-mediated paralysis. Calcium chloride (CaCl 2 ) overload was also tested for an effect on Aβ-mediated paralysis. A) Effect of CaI on Aβ-mediated paralysis in CL4176 worms. B) Effect of CaI on the ability of 5 mM MICA to alleviate Aβ-mediated paralysis. C) Effect of CaI on the ability of dld-1 RNAi to alleviate Aβ-mediated paralysis. D) Effect of CaCl 2 overload on Aβ-mediated paralysis. The temperature for this assay was 24°C. Results are derived from three independent replicates and are given as the weighted average. Curve comparison used log-rank test. 60-80 worms were used for each replicate of each trial.
in a decrease in both dld-1 transcript and protein levels. In contrast, ≤10 mM MICA did not change the DLD protein expression levels when compared to control while a dose of 15 mM MICA triggered an increase in DLD-1 protein levels, presumably reflecting an attempt to restore enzyme activity levels in the face of direct inhibition by MICA. Despite the elevated protein abundance following treatment with MICA, there was an increase in the ratio of non-toxic Aβ monomers to toxic oligomers (Diomede et al., 2014; Dosanjh et al., 2010; Dostal and Link, 2010; Link, 1995; McColl et al., 2012; Wu and Luo, 2005; Wu et al., 2006) . Consistent with the decrease in oligomerisation of Aβ in response to MICA, we observe that MICA can reduce the severity of symptoms triggered by Aβ. Specifically, MICA delayed the time-dependent paralysis induced by expression of Aβ in muscle. Such paralysis could be due to Aβ-mediated synaptic defects via inhibition of the cholinergic neurotransmission essential for neuromuscular activity (Brown and Luo, 2009; Oh and Kim, 2017; Wu et al., 2006; Xin et al., 2013) . We found that MICA did indeed restore sensitivity to activators of cholinergic signaling, which we interpreted as suppression of DLD enzyme activity by MICA, resulting in a decrease in oligomerisation of Aβ, leading to improvement in cholinergic neurotransmission. The protective effect of MICA was not apparent at higher doses through a mechanism independent of Aβ. The most likely interpretation is that MICA at high doses, had a deleterious effect on DLD-mediated energy metabolism, or caused other side-effects unrelated to DLD.
We also tested the ability of MICA to positively influence cellular function when Aβ was expressed in C. elegans neuronal cells. Aβ expression is associated with neuronal dysfunction leading to reduced chemotaxis, serotonin hypersensitivity, impaired fecundity and delayed egg hatching (Machino et al., 2014; Wu et al., 2006) , each of which is influenced by impaired ACh signaling (Rand, 2007) . Just as MICA restored cholinergic neurotransmission in worms that express Aβ in muscle cells, we reasoned that MICA should also reduce Aβ-mediated toxicity in worms that express Aβ in neurons. In our previous study, we found that metformin, a well-known hypoglycemic agent, improved chemotaxis and restored normal serotonin-sensitivity in worms that express Aβ in neurons (Ahmad and Ebert, 2016) . Similar findings were observed for MICA in this study showing that the two metabolically active compounds are able to achieve the same therapeutic endpoint. Aβ oligomerization and accumulation inhibits cholinergic neurotransmission, impairs calcium signaling and blocks serotonin re-uptake (Wu et al., 2006) , each of which cause hypersensitivity to serotonin. Chemotaxis in C. elegans is directly controlled by serotonin, making it a suitable indicator of proper serotonin signaling (Tsui and van der Kooy, 2008) . MICA has no affinity for serotonin receptors (AppelDingemanse, 2002 ) and has no effect on serotonin sensitivity in control nematodes that do not express Aβ. Thus, the ability of MICA to enhance chemotaxis in transgenic worms is most likely due to a decrease in Aβ pathology leading to restoration of normal ACh neurotransmission, and thereby, normal serotonin sensitivity as well.
Aβ expression also reduced fecundity and delayed egg hatching in C. elegans (Machino et al., 2014) . MICA partially reversed the effect of Aβ expression, but also negatively affected these traits in control worms that did not express Aβ. The overall effect of MICA on reproduction was deleterious. MICA has also been found to decrease fertility in mammals (Panneerdoss et al., 2012) , so a similar observation in worms is not surprising. We postulate that the increase in fertility of worms that express Aβ is due to modulation of Aβ toxicity caused by oligomerisation, whereas higher doses of MICA are deleterious because they disrupt DLD function and thereby the energy balance too severely.
The preceding results demonstrate that MICA can reduce Aβ-proteotoxicity in C. elegans. To elucidate possible mechanisms, we assessed the role of calcium signaling on the ability of MICA to protect against Aβ-toxicity, including effects on the production and oligomerization of Aβ peptide. Calcium is known to positively regulate the activity of DLDcontaining enzyme complexes, so could be expected to counter the beneficial effects of complex inhibition due to exposure to MICA. A calcium ionophore (CaI) acts by releasing calcium from cellular stores, thereby increasing intracellular calcium levels (Bauman and Hill, 1968; Panneerdoss et al., 2012) . This provides a way to test the interaction between MICA-mediated DLD inhibition and calcium-mediated activation of the DLD-containing enzyme complexes. Indeed, CaI increased Aβ-mediated paralysis dose dependently and reversed the protective effects of dld-1 gene suppression. CaI was previously found to reverse the ability of MICA to inhibit DLD enzyme activity in acrosomes (Kumar et al., 2008; Panneerdoss et al., 2012) . The same mechanism could explain our observations. Impaired calcium homeostasis in aging brains is well documented, suggesting that this could exacerbate age-related neurodegeneration (Mattson and Chan, 2001; Woods and Padmanabhan, 2012) . We also tested the effect of an increase in extracellular calcium on Aβ-proteotoxicity, but increasing the calcium in the growth medium from 1 mM to 10 mM had no effect on the Aβ-mediated paralysis phenotype. This indicates that the external calcium pool has minimal effect on intracellular calcium levels in the worm.
Given that CaI reversed the protective effect of DLD inhibition Fig. 6 . Effect of MICA and CaI on Aβ transgene and protein expression. Aβ was induced in muscles of strain CL4176 by a temperature up shift in worms in which the dld-1 gene was suppressed by RNAi, the enzyme was inhibited by 5 mM MICA or 35 μM CaI was administered either alone or in combination with the other treatments. (A) Quantitative PCR revealed that none of dld-1 RNAi, MICA or CaI had any significant effect on Aβ mRNA levels. (B) A representative western blot of protein extracted from worms of strain CL4176 is shown in the bottom of panel B. Aβ was detected using Anti-Aβ antibody 6E10, with antiactin antibody used to detect actin protein, which served as a normalization reference. Aβ 4 kDa and 16kda peptide intensity levels were quantified relative to the control. Results from 3 independent experiments shown in the upper portion of panel B. Bars = Mean ± SD.
against Aβ-mediated paralysis, we also examined the effect of CaI on oligomerization of Aβ. We found that CaI induced Aβ oligomerization despite suppression of the dld-1 gene by RNAi. This suggests that enzyme activation by Ca 2+ can reverse protection against the toxicity of Aβ provided by suppression of the dld-1 gene. Surprisingly, exposure to CaI reduced oligomerization of Aβ in worms that expressed Aβ, but in which the dld-1 gene was not suppressed by RNAi. In addition to a decrease in Aβ oligomerization, a decrease in oxidative stress could also be a protective mechanism resulting from DLD inhibition by MICA in the Aβ-expressing strain, as ROS is negatively coorelated with Aβ aggregate formation (Misonou et al., 2000; Pajak et al., 2016) . DLD itself can generate a significant amount of ROS (superoxide). As such, suppression of DLD activity could lead to a decrease in superoxide production and thereby a decrease in cellular oxidative stress. The superoxide radical (O 2 .- ) is readily converted into H 2 O 2 or reacts with nitrogenous species to form reactive nitrogen compounds (Murphy, 2009; Tahara et al., 2007) . In our study, MICA treatment decreased overall ROS/RNS levels as detected by DCDFA and also decreased the amount of H 2 O 2 . A recent study in rats also observed same findings where MICA not only decreased H2O2 levels but also reduced protein carbonylation and lipid peroxidation (Wu et al., 2018) . The decrease in ROS/RNS in response to inhibition of DLD activity provides another probable mechanism to explain the protective effect of MICA against Aβ-toxicity. Overall, the protective effect of MICA seems to occur through inhibition of Aβ oligomerization either by a decrease in oxidative stress, or by modulation of calcium signaling. Although we did not assess the role of CaI on ROS/RNS levels, it may be that CaI also induces oxidative stress as reported in previous studies (Petersen et al., 2000; Przygodzki et al., 2005; Yamazaki et al., 2009) .
Although MICA was first proposed as a drug for diabetes 65 years ago, development of this compound has not been pursued due to significant side-effects. We demonstrate that MICA provides significant protection against Aβ-mediated pathology in the C. elegans model of AD. This suggests that the wide array of commercially available MICA derivatives or other compounds that target DLD or the DLD-containing enzyme complexes should be investigated as potential therapeutic compounds for the treatment of AD.
